Drug Trial Radar · NCT05145218
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Dec 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
405
Planned (sponsor's estimate)
Start
Sep 28, 2021
Primary completion
Oct 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus weekly treatment with paclitaxel of recurrent platinum-resistant ovarian cancer.A total of 405 subjects will be enrolled.
Conditions
- Recurrent Platinum-resistant Ovarian Cancer
Interventions
Anlotinib Hydrochloride CapsulesDrug
Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
Paclitaxel injectionDrug
Paclitaxel is a novel anti-microtubule agent.
TQB2450 injectionDrug
TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease progression-free survival(PFS) evaluated by Independent Review Committee(IRC)Time frame: Baseline up to two years
- Overall survival (OS)Time frame: Baseline up to two years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
AnYang Tumor Hospital
Anyang, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.